The #FierceMadness Final Four: Brineura, Trulance, Zepatier and Imfinzi cut down the nets

drug names bracket FPMK
Final Four time for FierceMadness: Will BioMarin's Brineura keep up its blistering pace?

We're down to four, folks. The #FierceMadness Final Four field is set after an Elite Eight that featured both blowouts and close calls.

With the most voters to date chiming in, Brineura decimated Luxturna by a score of 856-218. Let’s take a moment to give a nod to the power of BioMarin's public relations and employee determination. This time many BioMarinites embraced their company love, with several co-opting a previous voter’s dislike for “BioMarin’s kumbaya thing” by adopting the idea with comments like, “BioMarin Kumbaya FTW” and “Because I like singing kumbaya!”

When it works, it works. Next up, the BioMarin Brineura machine will take on Merck’s Zepatier.

Free Daily Newsletter

Like this story? Subscribe to FiercePharma!

Biopharma is a fast-growing world where big ideas come along daily. Our subscribers rely on FiercePharma as their must-read source for the latest news, analysis and data on drugs and the companies that make them. Sign up today to get pharma news and updates delivered to your inbox and read on the go.

On the flip side, in the closest race we’ve had in the tournament, Imfinzi barely edged Yescarta in a 287-285 one-possession win. The comments were just as split as the vote count. On the pro-Yescarta team, voters said, “Yes in the name makes it actionable sounding,” or simply, “Yes, this car-t will make the final four!” However, the Imfinzi group with the infinity puns and plays on "I’m fine" were too strong in the end. One commenter correctly predicted, “Imfinzi—the suggestion of infinity over a simple ‘yes’ prevails every time.”

In other contests, Synergy’s Trulance handily defeated Ingrezza 413-199, with most pro-Trulance voters going for the easier-to-pronounce, straight and “true choice.” Meanwhile, Zepatier downed Ozempic by a score of 304-261 with the “long-lost Musketeer” taking the win.

Final Four voting begins now and will continue through Sunday night at 10 p.m. ET. It’s a long round, so there’s plenty of time to rally the voting troops and push your favorites to victory. We’ll be back Monday with the last two standing!

 

Final Four (Vote here)

(1) Zepatier vs. (10) Brineura

Zepatier
Maker: Merck
Indication: hepatitis C
Sounds like: the guy who drives the Zeppelin

Brineura
Maker: BioMarin
Indication: CLN2 disease
Sounds like: a saltwater shrimp species

(5) Imfinzi vs. (1) Trulance

Imfinzi
Maker: AstraZeneca
Indication: unresectable Stage III non-small cell lung cancer and bladder cancer
Sounds like: when something will never, ever, ever happen again

Trulance
Maker: Synergy Pharmaceuticals
Indication: chronic idiopathic constipation and IBS-C
Sounds like: a weapon used by King Arthur’s knights

Suggested Articles

Alcon has many "mass and structural advantages" over "distant" follower Bausch, which spends a lot less on R&D, says one analyst.

The judge in a multistate case against opioid makers scoffed at their request for more time to review an estimate that they owe $480 billion in damages.

Indian drugmakers pick up U.S. generics scripts; Chi-Med files for Hong Kong listing; an explosion at a Qilu Pharma subsidiary kills 10.